CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Elicit Therapeutics Inc. - ELTX CFD

8.8166
0.11%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.1968
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 8.8066
Open 8.4766
1-Year Change 1056.43%
Day's Range 8.2066 - 8.9766
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
May 21, 2024 8.8066 -1.0700 -10.83% 9.8766 9.8766 8.4766
May 20, 2024 9.8066 -0.2400 -2.39% 10.0466 10.1366 9.4766
May 17, 2024 10.0066 0.1800 1.83% 9.8266 10.2266 9.4666
May 16, 2024 9.2666 -1.1100 -10.70% 10.3766 10.8366 8.3166
May 15, 2024 10.2866 -0.1400 -1.34% 10.4266 10.4566 10.0866
May 14, 2024 10.1866 0.7100 7.49% 9.4766 10.3766 9.4766
May 13, 2024 9.5566 0.0800 0.84% 9.4766 9.6266 9.1866
May 10, 2024 9.2566 -0.0300 -0.32% 9.2866 9.6366 9.1766
May 9, 2024 9.2754 -0.0600 -0.64% 9.3354 9.5254 9.1754
May 8, 2024 9.1654 0.1400 1.55% 9.0254 9.3754 8.8354
May 7, 2024 8.9254 0.0500 0.56% 8.8754 9.1154 8.7354
May 6, 2024 8.8854 -0.0700 -0.78% 8.9554 9.0254 8.7354
May 3, 2024 8.8954 0.0000 0.00% 8.8954 9.1754 8.7754
May 2, 2024 8.9054 0.0300 0.34% 8.8754 8.9254 8.7754
May 1, 2024 8.7954 -0.2000 -2.22% 8.9954 9.0954 8.7754
Apr 30, 2024 9.1454 0.2500 2.81% 8.8954 9.1454 8.6754
Apr 29, 2024 9.0354 0.0500 0.56% 8.9854 9.0754 8.5654
Apr 26, 2024 8.8654 -0.1100 -1.23% 8.9754 9.0754 8.4754
Apr 25, 2024 9.0254 0.1500 1.69% 8.8754 9.0754 8.8754
Apr 24, 2024 9.1854 0.0100 0.11% 9.1754 9.2954 8.8154

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Angion Biomedica Corp. Company profile

About Angion Biomedica Corp

Angion Biomedica Corp. is a late-stage biopharmaceutical company. The Company focuses on discovery, development and commercialization of small molecule therapeutics to address acute organ injuries and fibrotic diseases. The Company’s lead product candidate is ANG-3777. Its pipeline includes ANG-3070, rho kinase 2 (ROCK2), and CYP11B2. Its ANG-3777 is a hepatocyte growth factor (HGF) mimetic it is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other organs, such as the lungs, central nervous system (CNS) and heart. It is also evaluating ANG-3777 for indications within acute lung injury (ALI), with focus on acute respiratory distress syndrome (ARDS), as well as acute CNS injuries. The Company’s other programs are for the treatment of fibrotic diseases, ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).

Financial summary

BRIEF: For the nine months ended 30 September 2021, Angion Biomedica Corp revenues decreased 2% to $2.4M. Net loss increased 36% to $69.5M. Revenues reflect Grant revenue decrease from $2.4M to $0K. Higher net loss reflects Research and development - Balancing increase of 40% to $36.9M (expense), Other Non Operati decrease from $10K (income) to $3.6M (expense), Stock-based Compensation in R&D increase from $1.6M to $5.1M (expense).

Industry: Biotechnology & Medical Research (NEC)

451 D Street, 5Th Floor
BOSTON
MASSACHUSETTS 02459
US

News

UK CPI Preview: Will inflation return to 2% as the BoE predicts? And how will it affect GBP?

The latest round of inflation data will be released at 22 April at 7 am BST and investors are likely going to be paying close attention.

15:44, 21 May 2024

Reserve Bank of New Zealand Preview: RBNZ could become more dovish as inflation eases and growth softens

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, May 22, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

15:29, 21 May 2024

Nvidia Q1 Earnings Preview: Analysts forecast another blockbuster set of results

Nvidia (NVDA) reports its Q1 results after the closing bell on Wednesday, May 22nd. We preview what to expect from Nvidia’s earnings and analyse its stock's technicals.

14:57, 21 May 2024
CPI, consumer price index symbol.

Disinflation resumes in the US as CPI drops in April

The rate of growth in US consumer prices dropped in April leading markets to price in more chances of rate cuts from the Fed

11:24, 16 May 2024

Stock market crash: how far can the S&P 500 go?

After a remarkably strong first quarter, the US stock market pulled back in April for the first time since October last year.

11:46, 10 May 2024

Bank of England preview: possible rate cut in summer?

The Bank of England (BoE) is widely expected to keep interest rates unchanged when it meets later this week. Data from Reuters shows a 90% chance of no change to the current rate of 5.25%, but the central bank will need to decide whether to change the messaging about rate cuts this year as traders will be paying close attention to any rate-cut clues.

12:39, 8 May 2024

We’re partnering with Newsquawk

Filter out the noise and focus on the news that matters.

08:32, 23 April 2024

People also watch

Gold

2,374.74 Price
-1.870% 1D Chg, %
Long position overnight fee -0.0197%
Short position overnight fee 0.0115%
Overnight fee time 21:00 (UTC)
Spread 0.50

XRP/USD

0.53 Price
-2.460% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Oil - Crude

76.85 Price
-1.660% 1D Chg, %
Long position overnight fee 0.0052%
Short position overnight fee -0.0271%
Overnight fee time 21:00 (UTC)
Spread 0.030

US100

18,809.80 Price
+0.430% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading